Ken Griffin Collegium Pharmaceutical, Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 21,000 shares of COLL stock, worth $613,620. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,000

Previous 23,400 10.26%

Holding current value

$613,620

Previous $753,000 7.7%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$31.4 - $39.07 $1.3 Million - $1.61 Million	-41,326 Reduced 23.93%	131,344 $5.08 Million
Q2 2024 Aug 14, 2024	BUY	$31.36 - $39.99 $1.88 Million - $2.4 Million	59,927 Added 53.15%	172,670 $5.56 Million
Q1 2024 May 15, 2024	BUY	$31.23 - $40.91 $69,799 - $91,433	2,235 Added 2.02%	112,743 $4.38 Million
Q4 2023 Feb 14, 2024	BUY	$21.16 - $30.8 $2.34 Million - $3.4 Million	110,508 New	110,508 $3.4 Million
Q2 2023 Aug 14, 2023	SELL	$21.06 - $24.0 $2.31 Million - $2.64 Million	-109,820 Reduced 58.93%	76,543 $1.64 Million
Q1 2023 May 15, 2023	BUY	$23.0 - $29.88 $1.48 Million - $1.92 Million	64,241 Added 52.6%	186,363 $4.47 Million
Q4 2022 Feb 14, 2023	BUY	$16.14 - $23.55 $205,510 - $299,862	12,733 Added 11.64%	122,122 $2.83 Million
Q3 2022 Nov 14, 2022	SELL	$15.46 - $20.1 $849,032 - $1.1 Million	-54,918 Reduced 33.42%	109,389 $1.75 Million
Q2 2022 Aug 15, 2022	BUY	$14.22 - $20.88 $821,660 - $1.21 Million	57,782 Added 54.24%	164,307 $2.91 Million
Q1 2022 May 16, 2022	BUY	$17.2 - $22.5 $1.42 Million - $1.86 Million	82,592 Added 345.1%	106,525 $2.17 Million
Q3 2021 Nov 15, 2021	BUY	$17.75 - $25.39 $57,882 - $82,796	3,261 Added 15.77%	23,933 $473,000
Q2 2021 Aug 16, 2021	SELL	$21.74 - $25.28 $645,351 - $750,436	-29,685 Reduced 58.95%	20,672 $488,000
Q1 2021 May 17, 2021	SELL	$19.25 - $26.1 $1.22 Million - $1.65 Million	-63,309 Reduced 55.7%	50,357 $1.19 Million
Q4 2020 Feb 16, 2021	BUY	$17.83 - $22.29 $694,014 - $867,615	38,924 Added 52.08%	113,666 $2.28 Million
Q3 2020 Nov 16, 2020	BUY	$15.78 - $20.82 $837,854 - $1.11 Million	53,096 Added 245.29%	74,742 $1.56 Million
Q2 2020 Aug 14, 2020	SELL	$15.49 - $23.51 $1.94 Million - $2.95 Million	-125,519 Reduced 85.29%	21,646 $379,000
Q1 2020 May 15, 2020	BUY	$13.89 - $25.45 $2.04 Million - $3.75 Million	147,165 New	147,165 $2.4 Million
Q4 2019 Feb 14, 2020	SELL	$10.7 - $22.24 $116,341 - $241,815	-10,873 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$10.16 - $13.28 $236,016 - $308,494	-23,230 Reduced 68.12%	10,873 $124,000
Q2 2019 Aug 14, 2019	SELL	$10.62 - $16.59 $1.33 Million - $2.07 Million	-124,884 Reduced 78.55%	34,103 $448,000
Q1 2019 May 15, 2019	BUY	$13.58 - $18.72 $674,491 - $929,784	49,668 Added 45.43%	158,987 $0
Q4 2018 Feb 14, 2019	SELL	$14.78 - $19.68 $1.2 Million - $1.6 Million	-81,437 Reduced 42.69%	109,319 $1.88 Million
Q3 2018 Nov 13, 2018	BUY	$14.16 - $24.3 $2.41 Million - $4.14 Million	170,197 Added 827.85%	190,756 $0
Q2 2018 Aug 10, 2018	SELL	$21.79 - $28.29 $6.93 Million - $9 Million	-318,250 Reduced 93.93%	20,559 $0
Q1 2018 May 11, 2018	SELL	$18.15 - $29.21 $9.47 Million - $15.2 Million	-521,918 Reduced 60.64%	338,809 $8.66 Million
Q4 2017 Feb 09, 2018	BUY	$9.3 - $19.14 $2.95 Million - $6.06 Million	316,694 Added 58.21%	860,727 $15.9 Million
Q3 2017 Nov 09, 2017	BUY	$9.15 - $11.97 $4.98 Million - $6.51 Million	544,033	544,033 $5.71 Million

Others Institutions Holding COLL

# of Institutions

255

Shares Held

38.6M

Call Options Held

100K

Put Options Held

21.1K

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $997M
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account